Home › Acute Myeloid Leukemia › Kansas › Overland Park
Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Overland Park, KS
Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Overland Park. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Nagre-recruitPhase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Nagre-recruitPhase 3
- US-Kansas City KS-KUMC, Fairway · 3 mi ang layo
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Nagre-recruitPhase 1
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi ang layo
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- The University of Kansas Medical Center Research Institute, Fairway · 3 mi ang layo
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Nagre-recruitPhase 1
- University of Kansas, Fairway · 3 mi ang layo
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Nagre-recruitPhase 2
- University of Kansas Cancer Center, Fairway · 3 mi ang layo
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Nagre-recruitPhase 1
- University of Kansas Cancer Center, Fairway · 3 mi ang layo
Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod
- Houston, TX85 pag-aaral
- New York City, NY51 pag-aaral
- Boston, MA44 pag-aaral
- Seattle, WA41 pag-aaral
- Baldwin Park, CA40 pag-aaral
- Columbus, OH35 pag-aaral
- Philadelphia, PA34 pag-aaral
- Durham, NC33 pag-aaral
- Atlanta, GA31 pag-aaral
- Tampa, FL29 pag-aaral
- Chicago, IL26 pag-aaral
- Portland, OR25 pag-aaral
Iba pang pag-aaral sa Overland Park
- Non-Small Cell Lung Cancer16 pag-aaral
- Kanser sa Baga11 pag-aaral
- Kanser sa Suso10 pag-aaral
- Atrial Fibrillation8 pag-aaral
- Colorectal Cancer8 pag-aaral
- Obesity7 pag-aaral
- Kanser sa Pancreas7 pag-aaral
- Kanser sa Prostate7 pag-aaral
- Melanoma6 pag-aaral
- Overweight6 pag-aaral
- Kanser sa Ovary6 pag-aaral
- Kanser (lahat ng uri)5 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.